Mirador Therapeutics

Mirador Therapeutics, Inc. is a San Diego, California-based clinical-stage precision medicine company developing first- and/or best-in-class therapeutics for immunology and inflammation (I&I), with a focus on immune-mediated inflammatory and fibrotic (immuno-fibrotic) diseases. The company's stated premise is that current I&I treatments have reached an efficacy ceiling, with many patients experiencing lack of response, insufficient response, intolerance or loss of response, and that precision medicine approaches long applied in oncology have not been widely extended to immune-mediated and fibrotic conditions.

Mirador's programs span Crohn's disease, ulcerative colitis, rheumatoid arthritis and idiopathic pulmonary fibrosis. As of January 2026 the company said it had advanced multiple clinical-stage assets across these four indications in less than two years and was pursuing a parallel development strategy intended to de-risk its multi-asset portfolio, with 10 or more clinical readouts expected by year-end 2027. In July 2026 the company announced an exclusive license to KP-301, a long-acting anti-C5a antibody, expanding its precision immunology portfolio.

Founding story

Mirador was founded by Mark C. McKenna, who serves as chairman and CEO, together with several other former executives of Prometheus Biosciences, a company acquired in 2023. The founding thesis was that an end-to-end precision medicine strategy was needed to overcome persistent challenges in developing effective, tailored treatments for immune-mediated conditions. The company publicly launched on March 21, 2024. One source dates the company's founding to 2023 and another to 2024; the company itself dates its launch to March 2024. The name "Mirador" is Spanish for "vantage point" or "lookout."

Business model

Mirador is a therapeutics developer that discovers and develops proprietary drug candidates, funded to date by private venture and crossover investment. It also in-licenses external assets, as with the exclusive license to KP-301 announced in July 2026. No revenue-generating products are described in the sources.

Traction

Mirador reported multiple clinical-stage assets across four indications within two years of launch, with 10 or more clinical readouts expected by year-end 2027, and more than $650 million raised in total. It was named an "Endpoints 11" winner in 2024. Employee counts reported by third parties vary widely (one source lists 94 employees; another lists an 1,001-5,000 range and another 11-50).

Latest developments

On January 12, 2026 Mirador announced the close of a $250 million Series B (completed in Q3 2025) with new investors T. Rowe Price Investment Management, Adage Capital Partners and additional Fidelity-managed funds, plus Series A participants, and outlined clinical progress across Crohn's disease, ulcerative colitis, rheumatoid arthritis and idiopathic pulmonary fibrosis. On July 16, 2026 the company announced an exclusive license to KP-301, a long-acting anti-C5a antibody, to expand its precision immunology portfolio.